[go: up one dir, main page]

MX2014002963A - Anticuerpo anti - receptor de linfocitos t alfa - beta. - Google Patents

Anticuerpo anti - receptor de linfocitos t alfa - beta.

Info

Publication number
MX2014002963A
MX2014002963A MX2014002963A MX2014002963A MX2014002963A MX 2014002963 A MX2014002963 A MX 2014002963A MX 2014002963 A MX2014002963 A MX 2014002963A MX 2014002963 A MX2014002963 A MX 2014002963A MX 2014002963 A MX2014002963 A MX 2014002963A
Authority
MX
Mexico
Prior art keywords
aplhabetatcr
antibody
aptcr
cdrs
bind
Prior art date
Application number
MX2014002963A
Other languages
English (en)
Other versions
MX355735B (es
Inventor
Andreas Menrad
Daniel Snell
Gina Lacorcia
Srinivas Shankara
Huawei Qiu
Clark Pan
Benjamin Kebble
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014002963(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2014002963A publication Critical patent/MX2014002963A/es
Publication of MX355735B publication Critical patent/MX355735B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a anticuerpos monoclonales humanizados que comprenden las CDRs del anticuerpo murino BMA031, que se une al complejo apTCR.CD3 y tiene propiedades biológicas mejoradas.
MX2014002963A 2011-09-12 2012-09-12 Anticuerpo anti - receptor de linfocitos t alfa - beta. MX355735B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161533510P 2011-09-12 2011-09-12
PCT/EP2012/003819 WO2013037484A2 (en) 2011-09-12 2012-09-12 Anti-aplhabetatcr antibody

Publications (2)

Publication Number Publication Date
MX2014002963A true MX2014002963A (es) 2015-03-19
MX355735B MX355735B (es) 2018-04-27

Family

ID=46851393

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005271A MX379660B (es) 2011-09-12 2012-09-12 Anticuerpo anti-receptor de linfocitos t alfa-beta.
MX2014002963A MX355735B (es) 2011-09-12 2012-09-12 Anticuerpo anti - receptor de linfocitos t alfa - beta.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018005271A MX379660B (es) 2011-09-12 2012-09-12 Anticuerpo anti-receptor de linfocitos t alfa-beta.

Country Status (34)

Country Link
US (3) US10017573B2 (es)
EP (1) EP2755999B1 (es)
JP (2) JP6096196B2 (es)
KR (1) KR20140072092A (es)
CN (3) CN119119269A (es)
AU (2) AU2012307816C1 (es)
BR (2) BR112014005644A2 (es)
CA (1) CA2847949C (es)
CL (2) CL2014000574A1 (es)
CO (1) CO6930307A2 (es)
CR (1) CR20140127A (es)
DK (1) DK2755999T3 (es)
DO (1) DOP2014000052A (es)
EC (1) ECSP14013307A (es)
ES (1) ES2667893T3 (es)
GT (1) GT201400045A (es)
HU (1) HUE037470T2 (es)
IL (2) IL231304B (es)
LT (1) LT2755999T (es)
MA (1) MA35711B1 (es)
MX (2) MX379660B (es)
MY (1) MY173924A (es)
NI (1) NI201400019A (es)
PE (1) PE20141548A1 (es)
PH (1) PH12014500408A1 (es)
PL (1) PL2755999T3 (es)
PT (1) PT2755999T (es)
RU (2) RU2017129721A (es)
SG (2) SG10201601738UA (es)
TN (1) TN2014000107A1 (es)
TW (1) TWI593706B (es)
UA (1) UA115533C2 (es)
UY (1) UY34317A (es)
WO (1) WO2013037484A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
MY170126A (en) * 2012-09-12 2019-07-05 Genzyme Corp Fc containing polypeptides with altered glycosylation and reduced effector function
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
IL289918B2 (en) 2013-03-11 2025-07-01 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
CA2928756A1 (en) * 2013-10-30 2015-05-07 Genzyme Corporation Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
ES3051373T3 (en) 2014-03-19 2025-12-26 Genzyme Corp Site-specific glycoengineering of targeting moieties
EP3799887A1 (en) * 2014-10-09 2021-04-07 Genzyme Corporation Glycoengineered antibody drug conjugates
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
AU2016273215B2 (en) * 2015-06-01 2019-04-11 Medigene Immunotherapies Gmbh T-cell receptor specific antibodies
MX2018004721A (es) * 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
PT3652215T (pt) 2017-07-14 2021-05-18 Immatics Biotechnologies Gmbh Molécula de polipéptido com especificidade dupla melhorada
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
RU2708558C1 (ru) * 2018-12-13 2019-12-09 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN113122503B (zh) * 2019-12-30 2022-10-11 博雅缉因（北京）生物科技有限公司 一种靶向t细胞淋巴瘤细胞的通用型car-t及其制备方法和应用
CN113122504A (zh) * 2019-12-30 2021-07-16 博雅辑因（北京）生物科技有限公司 一种纯化ucart细胞的方法与应用
CN114867850A (zh) * 2019-12-30 2022-08-05 博雅缉因（北京）生物科技有限公司 一种纯化ucart细胞的方法与应用
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN113088495B (zh) * 2020-01-09 2024-08-16 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CN119233999A (zh) * 2022-05-25 2024-12-31 羿尊生物医药（浙江）有限公司 靶向细胞膜受体蛋白的融合蛋白及其应用

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5149782A (en) 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
DE68928427T2 (de) 1988-09-15 1998-06-04 Univ Columbia Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5792456A (en) 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
ATE208633T1 (de) 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
UA71889C2 (uk) 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
WO1998005787A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1115740A1 (en) 1998-09-23 2001-07-18 The Regents of the University of California Synthetic peptides, conjugation reagents and methods
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
CN1110322C (zh) 1999-07-21 2003-06-04 中国医学科学院医药生物技术研究所 单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
ES2562177T3 (es) 2002-09-27 2016-03-02 Xencor Inc. Variantes de Fc optimizadas y métodos para su generación
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
RU2392324C2 (ru) * 2003-09-18 2010-06-20 Симфоген А/С Способ связывания интересующих последовательностей
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US7001978B2 (en) 2003-11-19 2006-02-21 Xerox Corporation Unsaturated ester substituted polymers with reduced halogen content
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
BRPI0506771A (pt) 2004-01-12 2007-05-22 Applied Molecular Evolution anticorpo, e, composição farmacêutica
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
BRPI0510295A (pt) 2004-05-04 2007-11-06 Novo Nordisk Healthcare Ag preparação de uma glicoproteìna, e, método para produzir a mesma
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US20060084145A1 (en) 2004-09-27 2006-04-20 Anderson Glenn M sRAGE mimetibody, compositions, methods and uses
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
JP4829609B2 (ja) * 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
CA2611519A1 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
AU2006265676B2 (en) 2005-06-30 2013-01-24 Centocor, Inc. Methods and compositions with enhanced therapeutic activity
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CZ297081B6 (cs) 2005-10-03 2006-09-13 Flek@Jaroslav Zubní kartácek
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
JP5597793B2 (ja) * 2006-06-19 2014-10-01 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｌｔ３結合分子およびその使用
FI20060946A0 (fi) 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
JP2010512306A (ja) 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
MX2009007375A (es) 2007-01-09 2009-07-21 Biogen Idec Inc Anticuerpos sp35 y usos de los mismos.
EP2125893A2 (en) 2007-01-23 2009-12-02 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
EP2205258B1 (en) 2007-09-28 2017-05-24 Janssen Biotech, Inc. Methods and structural conformations of antibody preparations with increased resistance to proteases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
WO2009089396A2 (en) 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
EP2811017A2 (en) 2008-04-21 2014-12-10 Novo Nordisk Health Care AG Hyperglycosylated human coagulation factor IX
UA40611U (ru) 2008-05-26 2009-04-27 Владимир Семенович Живченко Способ десульфурации железоуглеродистого расплава в тигельной печи
WO2010027797A1 (en) * 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
LT2542256T (lt) * 2010-03-04 2019-10-25 Macrogenics Inc Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
JP6334166B2 (ja) 2010-08-10 2018-05-30 グリコトープ ゲーエムベーハー Ｆａｂグリコシル化抗体
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
SG193379A1 (en) 2011-03-11 2013-10-30 Amicus Therapeutics Inc Dosing regimens for the treatment of fabry disease
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
MY170126A (en) 2012-09-12 2019-07-05 Genzyme Corp Fc containing polypeptides with altered glycosylation and reduced effector function
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
IL289918B2 (en) 2013-03-11 2025-07-01 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
ES3051373T3 (en) 2014-03-19 2025-12-26 Genzyme Corp Site-specific glycoengineering of targeting moieties
CA2944539A1 (en) 2014-04-08 2015-10-15 University Of Georgia Research Foundation, Inc. Site-specific antibody-drug glycoconjugates and methods
EP3799887A1 (en) 2014-10-09 2021-04-07 Genzyme Corporation Glycoengineered antibody drug conjugates
US10280317B2 (en) 2016-07-07 2019-05-07 Northwestern University Enhanced conductivity, adhesion and environmental stability of printed graphene inks with nitrocellulose

Also Published As

Publication number Publication date
NZ623656A (en) 2016-04-29
AU2012307816B2 (en) 2017-08-17
JP6599911B2 (ja) 2019-10-30
KR20140072092A (ko) 2014-06-12
AU2012307816A1 (en) 2014-04-24
DK2755999T3 (en) 2018-05-22
ES2667893T3 (es) 2018-05-14
IL231304A0 (en) 2014-04-30
RU2014114527A (ru) 2015-10-20
JP2017108752A (ja) 2017-06-22
PL2755999T3 (pl) 2018-09-28
WO2013037484A2 (en) 2013-03-21
HK1199268A1 (en) 2015-08-07
TWI593706B (zh) 2017-08-01
IL259826A (en) 2018-07-31
RU2017129721A3 (es) 2019-02-06
MX355735B (es) 2018-04-27
AU2012307816C1 (en) 2017-12-07
EP2755999A2 (en) 2014-07-23
CN110272492A (zh) 2019-09-24
WO2013037484A3 (en) 2013-08-29
WO2013037484A8 (en) 2014-05-22
CR20140127A (es) 2014-08-20
BR112014005644A2 (pt) 2017-03-28
RU2630656C2 (ru) 2017-09-11
MA35711B1 (fr) 2014-12-01
CN104684930A (zh) 2015-06-03
BR122021001193B1 (pt) 2023-05-16
CN119119269A (zh) 2024-12-13
UA115533C2 (uk) 2017-11-27
PH12014500408A1 (en) 2022-04-18
US20150099861A1 (en) 2015-04-09
JP2014527802A (ja) 2014-10-23
PT2755999T (pt) 2018-05-14
CA2847949A1 (en) 2013-03-21
LT2755999T (lt) 2018-05-10
SG10201601738UA (en) 2016-04-28
AU2017261557B2 (en) 2019-11-14
HUE037470T2 (hu) 2018-08-28
AU2017261557A1 (en) 2017-12-07
MY173924A (en) 2020-02-27
US11186638B2 (en) 2021-11-30
CN104684930B (zh) 2019-04-26
EP2755999B1 (en) 2018-01-31
IL231304B (en) 2018-06-28
AU2012307816A8 (en) 2014-06-19
US20220153841A1 (en) 2022-05-19
CO6930307A2 (es) 2014-04-28
UY34317A (es) 2013-02-28
TW201313741A (zh) 2013-04-01
CL2017001730A1 (es) 2018-03-16
NI201400019A (es) 2014-10-10
DOP2014000052A (es) 2014-09-15
MX379660B (es) 2025-03-11
NZ717726A (en) 2017-11-24
TN2014000107A1 (en) 2015-07-01
ECSP14013307A (es) 2015-04-30
GT201400045A (es) 2015-07-29
PE20141548A1 (es) 2014-11-18
CA2847949C (en) 2019-12-03
JP6096196B2 (ja) 2017-03-15
CL2014000574A1 (es) 2015-04-10
RU2017129721A (ru) 2019-02-06
US10017573B2 (en) 2018-07-10
SG11201400126PA (en) 2014-03-28
US20180237522A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
TN2014000107A1 (en) Anti-aplhabetatcr antibody
IL268369A (en) Anti-CD3 antibodies, bispecific-antigen-binding compounds that bind CD3 and CD20, and their uses
MX2013009362A (es) Anticuerpo contra el csf-1r.
NZ629913A (en) Anti-ox40 antibodies and methods of using the same
NZ608318A (en) Anti-cxcl13 antibodies and methods of using the same
NZ602294A (en) Monoclonal antibodies against c-met
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
NZ602176A (en) Cd37-binding molecules and immunoconjugates thereof
MX2014010987A (es) Tratamiento de esclerosis multiple con anticuerpo anti-cd19.
WO2013186630A3 (en) Humanized antibodies to ca215
NZ737925A (en) Monoclonal antibodies against c-met
TH98689B (th) ฮิวแมไนซ์แอนติบอดีที่จดจำแอลฟา-ไซนูคลีน

Legal Events

Date Code Title Description
FG Grant or registration